STAMFORD, Connecticut, July 15 10, 2022 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing drugs for patients with serious rare diseases and cancer, today announced the appointment of Carlos Albán to the Company’s Board of Directors. Mr. Albán, who served as Vice President and Chief Commercial Officer of AbbVie, Inc. (“AbbVie”) until his retirement last year, brings more than 30 years of experience in strategy and global business operations.
“Carlos’ success in building and leading global business organizations will be invaluable as SpringWorks continues its planned transition to a business enterprise over the coming year and we are excited to welcome him to our board of directors. administration,” said Saqib Islam, CEO of SpringWorks.
“SpringWorks has an exciting opportunity ahead to bring first-in-class, best-in-class medicines to patients with devastating rare diseases and cancers,” said Albán. “I look forward to working with the leadership team to help them achieve their ambitious goals and prepare to launch their first product.”
Mr. Albán joins the SpringWorks Board of Directors with significant leadership and business experience gained during his more than 30-year career in the pharmaceutical industry. Most recently, he served as vice president and chief commercial officer of AbbVie until his retirement in March 2021. Under his leadership, AbbVie’s sales grew from $18 billion in 2013 to more than $45 billion in 2020, making AbbVie the 5e largest pharmaceutical company in the world. Prior to this role, he was Executive Vice President, Commercial Operations and prior to AbbVie’s separation from Abbott, Mr. Albán served as AbbVie’s Senior Vice President, Proprietary Pharmaceuticals, Global Commercial Operations. He also held several leadership positions at Abbott Laboratories, Inc., including Senior Vice President, International Pharmaceuticals; Vice President, Pharmaceuticals, Western Europe and Canada Operations; Vice President, Pharmaceuticals, European Operations; regional director for the Northern Europe zone of the international pharmaceutical activity; and Managing Director, Portugal. Mr. Albán earned a degree in economics from the Pontificia Universidad Javeriana in Bogotá, Colombia.
About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquire, develop and commercialize life-changing medicines for patients with serious rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematologic cancers, including two potentially registered clinical trials in rare tumor types as well as several programs addressing highly prevalent genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development has enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry innovators. industry and academia to unlock the full potential of its portfolio. and create more solutions for cancer patients. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.
SpringWorks Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding our business, operations and financial conditions, including, but not limited to, beliefs , current expectations and assumptions. about our expanded, non-exclusive global clinical collaboration and licensing agreement with GSK plc, the the future of our business, our future plans and strategies, our development plans, our preclinical and clinical results, and other future conditions. Words such as, but not limited to, “look forward to”, “believe”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, ” would”, “should” and “could”, and similar expressions or words, identify forward-looking statements. New risks and uncertainties may arise from time to time and it is not possible to foresee all risks and uncertainties. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and factors that may cause actual events or results to differ. differ materially from those expressed or implied by any forward-looking statement. statements contained in this press release, including, without limitation, risks relating to: (i) the success and timing of our product development activities, including the initiation and completion of clinical trials of SpringWorks, (ii) the fact that primary or interim data from clinical studies may not be predictive of the final or more detailed results of such study, or the results of other ongoing or future studies, (iii) the success and the timing of ongoing and planned clinical trials of our collaborative partners, (iv) the timing of our planned regulatory submissions and interactions, and the timing and outcome of decisions made by the Food and Drug Administration (FDA) of United States and other regulatory agencies. regulatory authorities, research review boards at clinical trial sites and publication review bodies; (v) whether the FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or delay approval of our drug candidates, (vi) our ability to obtain and maintain regulatory approval of any of our product candidates, (vii) our plans to research, discover and develop additional product candidates, (viii) our ability to enter into new product candidate development collaborations, ( (ix) our ability to establish manufacturing capabilities, and our collaborations with those of our partners’ capabilities to manufacture our product candidates and scale up production, and (x) uncertainties and assumptions regarding the impact of the COVID-19 pandemic. 19 on SpringWorks’ business, operations, clinical trials, supply chain, strategy, goals and expected timelines.
Except as required by applicable law, we do not intend to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances or otherwise. . Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot guarantee that these expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements.
For additional information regarding risks, uncertainties and other factors that could cause SpringWorks’ expectations to differ from actual results, you should refer to “Risk Factors” in Item 1A of Part I of the Quarterly Report. from SpringWorks on Form 10-Q for the quarter. ended March 31, 2022, as well as discussions of potential risks, uncertainties, and other important factors in SpringWorks’ subsequent filings.
Vice President, Communications and Investor Relations
E-mail: [email protected]
Samantha Hilson Sandler
Director, Investor Relations
E-mail: [email protected]